Alievio
Alevio has developed a device for treating glaucoma to target intraocular pressure (IOP). The company has developed a small noninvasive device used to remove the intraocular pressure by draining the aqueous humor and enables the physicians to maintain the IOP by adjusting the pressure. The company claims that the outlet tube is as soft as a contact lens. Founded in 2010, headquartered in Durham, United States. The…
Funding snapshot
About
Alevio has developed a device for treating glaucoma to target intraocular pressure (IOP). The company has developed a small noninvasive device used to remove the intraocular pressure by draining the aqueous humor and enables the physicians to maintain the IOP by adjusting the pressure. The company claims that the outlet tube is as soft as a contact lens. Founded in 2010, headquartered in Durham, United States. The company has raised $12.2M in funding at the series a stage. The team comprises 3 ( The company operates in Life Sciences > Ophthalmology, High Tech > Wearable Technology, Internet of Things - Industry Applications > Wearable Technology. Its business models include Wearable Technology > Health and Wellness Devices > Eyecare, Ophthalmology > Medical Devices > Therapy > Glaucoma > Shunt. Founded in 2010. Headquartered in United States, Durham. The company has raised funding at the Series A stage. Backed by investors including America’s Seed Fund, NIH, Charlotte Angel Fund, Triangle Angel Partners, VCapital, InFocus Capital Partners, Pilot Mountain Ventures, Triangle Venture Alliance, First Flight Venture Center, IMAF Sandhills.
Business model
Wearable Technology > Health and Wellness Devices > Eyecare,
Ophthalmology > Medical Devices > Therapy > Glaucoma > Shunt
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.